Your Daily CRISPR & Gene Editing Briefing

FDA Clears Personalized CRISPR Therapy for Baby KJ in Record Time

• In a significant update, the U.S. Food and Drug Administration (FDA) cleared an individualized CRISPR therapy for "Baby KJ" in just one week, compressing a regulatory process that typically spans months. This rapid approval, detailed by University of Pennsylvania researcher Kiran Musunuru, involved a lipid-nanoparticle delivery platform repurposed to treat a fatal urea cycle disorder in the infant, who is now two years old and thriving without the need for a liver transplant. The case highlights the FDA's "plausible mechanism" pathway, designed to accelerate bespoke gene therapy development for ultra-rare diseases.

  BiggoBioryxa BlogPharmatica

• AstraZeneca has advanced templated editing technology with its Prime Editor nuclease (PEn) system, designed to enable efficient gene insertions while significantly reducing the risk of unintended large deletions. The company's latest research also demonstrates methods to boost editing specificity up to 9.8-fold and refine analytical techniques to examine editing outcomes cell by cell, providing a more detailed understanding of gene editing interactions with the genome.

  AstrazenecaPrnewswire

• The CRISPR market is projected to grow from USD 3.48 billion in 2026 to USD 6.12 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 12.0%. This expansion is driven by increasing adoption of gene-editing technologies in drug discovery, functional genomics, therapeutic development, and agricultural research, with North America accounting for the largest market share.

  Prnewswire